Management of Side Effects in Patients on Long-Term Aromatase Inhibitors

Bone Health Management

The National Comprehensive Cancer Network recommends baseline bone mineral density assessment via bone densitometry before starting AI therapy, particularly for patients at risk of osteoporosis 2
Daily calcium and vitamin D supplementation is recommended for all patients on AIs, as suggested by the National Comprehensive Cancer Network and the Annals of Oncology 1, 2
Regular monitoring of bone density during AI therapy is essential, according to the National Comprehensive Cancer Network 3, 4
For patients with T-scores between -1.0 and -2.5 (osteopenia) or lower than -2.5 (osteoporosis), consider bone-directed therapy, as recommended by the National Comprehensive Cancer Network 3, 5, 6

Oral bisphosphonates have shown favorable effects on BMD over 24 months in patients receiving anastrozole, as demonstrated by the National Comprehensive Cancer Network 4, 5, 6
Intravenous zoledronic acid has demonstrated preservation of BMD when used concurrently with letrozole, according to the National Comprehensive Cancer Network 3, 6
Denosumab has shown significant increases in lumbar spine BMD and hip BMD after 24 months in patients on AI therapy, as reported by the National Comprehensive Cancer Network 3, 6

Regular assessment for musculoskeletal symptoms at each clinical encounter is recommended, as suggested by the Journal of Clinical Oncology 7
Physical activity and exercise programs have been shown to decrease AI-associated pain by up to 20%, according to the Journal of Clinical Oncology 7
Acupuncture has demonstrated statistically significant improvement in AI-associated musculoskeletal symptoms, as reported by the Journal of Clinical Oncology 7

Monitor cardiovascular health during long-term AI therapy, as recommended by the Annals of Oncology 8, 9
Exemestane and letrozole have shown early signs of cardiac side effects compared to tamoxifen, while anastrozole has not demonstrated significant increases in ischemic cardiovascular disease, according to the Annals of Oncology 8, 9

Poor compliance with AI therapy has been associated with increased risk of breast cancer recurrence, as reported by the Journal of Clinical Oncology 7
Regular follow-up visits every 3-6 months for the first 3 years, every 6-12 months for the next 3 years, then annually to monitor for side effects, as recommended by the Annals of Oncology 1